Table 1.
Participant characteristics in the full analysis set
| Variables | Glimepiride (n = 68) | Sitagliptin (n = 65) |
|---|---|---|
| Male/female (number, %) | 49/19 (72.1/27.9 %) | 49/16 (75.4/24.6 %) |
| Age (year) | 64 (8) | 63 (9) |
| BMI (kg/m2) | 24.7 (3.3) | 24.1 (3.8) |
| Duration (year) | 6.0 (5.1) | 6.2 (6.0) |
| HbA1c (NGSP, %) | 7.5 (0.5) | 7.4 (0.5) |
| GA (%) | 19.5 (2.8) | 19.4 (2.7) |
| eGFR (ml/min/1.73 m2) | 74.9 (14.0) | 76.2 (17.1) |
| ISI (l2/mmol pmol) | 16.2 (9.2, 24.0) | 16.3 (10.2, 22.0) |
| Log transformed insulinogenic index (pmol/mmol) | 2.6 (2.1, 3.3) | 2.2 (1.9, 2.8) |
| Starting dose (mg/day) | 0.25 (20.6 %) | 25 (12.3 %) |
| 0.5 (77.9 %) | 50 (87.7 %) | |
| 1.0 (1.5 %) | 100 (0.0 %) |
Data are expressed as means (SD), median with interquartile range (IQR), number (%), or percent (%)
Data were analyzed ANOVA or Fisher’s Exact test
No significant differences were observed between the two groups
BMI body mass index, HbA1c hemoglobin A1c, ISI insulin sensitivity index, GA glycated albumin, eGFR estimated glomerular filtration rate